IP Library Assignment 072038/0693
Patent Assignment
Reel/Frame 072038/0693

Security Interest

Recorded: 2025-07-17 Pages: 16
Assignor
MADRIGAL PHARMACEUTICALS, INC.
Executed: 2025-07-17
Assignee
LSI FINANCING LLC, AS ADMINISTRATIVE AGENT
C/O BLUE OWL CAPITAL CORPORATION, 399 PARK AVENUE, 37TH FLOOR, NEW YORK, NEW YORK, 10022
Covered Properties (79)
Methods for Treating a Fatty Liver Disease
Application: 63/810,372 →
Methods for Treating a Fatty Liver Disease
Application: 63/805,404 →
Methods for Treating a Fatty Liver Disease
Application: 63/804,754 →
Methods for Treating a Fatty Liver Disease
Application: 63/802,904 →
Methods for Treating a Fatty Liver Disease
Application: 63/801,986 →
Methods for Treating a Fatty Liver Disease
Application: 19/045,070 →
Publication: US US20250249011A1
Methods for Treating a Fatty Liver Disease
Application: 63/721,474 →
Solid Forms of 2-(3,5-Dichloro-4-((5-Isopropyl-6-Oxo-1,6-Dihydropyridazin-3-Yl)Oxy)Phenyl)-3,5-Dioxo-2,3,4,5-Tetrahydro-1,2,4-Triazine-6-Carbonitrile
Application: 18/949,309 →
Publication: US US20250074898A1
Methods for Treating a Fatty Liver Disease
Application: 63/720,725 →
Methods for Treating a Fatty Liver Disease
Application: 63/719,257 →
Novel Thr Beta Analogs and Uses Thereof
Application: 18/837,378 →
Publication: US US20250154130A1
Biomarkers for Treating Liver Disorders with Thr-B Agonists and Related Uses
Application: 18/748,811 →
Publication: US US20240423992A1
Resmetirom for Reducing Liver Volume
Application: 18/695,572 →
Publication: US US20240408102A1
Method of Synthesizing Thyroid Hormone Analogs and Polymorphs Thereof
Application: 18/393,813 →
Publication: US US20240122936A1
Methods of Treating Liver Disorders or Lipid Disorders with a Thr-Beta Agonist
Application: 18/371,229 →
Publication: US US20240156826A1
Therapeutic Combinations of Rosuvastatin and Resmetirom for the Treatment of Liver Disorders or Lipid Disorders
Application: 18/263,546 →
Publication: US US20240307405A1
Methods for Preparing Pyridazinone Derivatives
Application: 18/032,895 →
Publication: US US20240051925A1
Methods of Treating Liver Disorders or Lipid Disorders with a Thr-Beta Agonist
Application: 17/369,197 →
Publication: US US20210330675A1
Methods of Synthesizing Thyroid Hormone Analogs and Polymorphs Thereof
Application: 17/118,706 →
Publication: US US20210161904A1
Combination Therapies Comprising Targeted Therapeutics
Application: 16/625,343 →
Publication: US US20200222374A1
Targeted Therapeutics
Application: 16/625,349 →
Publication: US US20200239472A1
Methods of Synthesizing Thyroid Hormone Analogs and Polymorphs Thereof
Application: 16/458,546 →
Publication: US US20190381053A1
Methods of Treating Liver Disorders or Lipid Disorders with a Thr-Beta Agonist
Application: 16/343,065 →
Publication: US US20200230146A1
Combination Therapy for Treatment of Ovarian Cancer
Application: 16/080,752 →
Publication: US US20190060285A1
Methods of Synthesizing Thyroid Hormone Analogs and Polymorphs Thereof
Application: 15/949,389 →
Publication: US US20180228807A1
Combination Therapy of HSP90 Inhibitors with Platinum-Containing Agents
Application: 15/940,055 →
Publication: US US20180221345A1
Combination Therapy of HSP90 Inhibitors and Pd-1 Inhibitors for Treating Cancer
Application: 15/549,866 →
Publication: US US20180064689A1
Targeted Therapeutics
Patent: 9,956,293 →
Application: 15/266,411 →
Publication: US US20170056511A1
Targeted Therapeutics
Application: 15/251,255 →
Publication: US US20170049899A1
Targeted Therapeutics
Application: 15/222,145 →
Publication: US US20170014519A1
Method of Synthesizing Thyroid Hormone Analogs and Polymorphs Thereof
Patent: 9,968,612 →
Application: 15/046,213 →
Publication: US US20160243126A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 9,206,162 →
Application: 14/685,178 →
Publication: US US20150266858A1
Method of Synthesizing Thyroid Hormone Analogs and Polymorphs Thereof
Patent: 9,266,861 →
Application: 14/660,720 →
Publication: US US20150203473A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 9,006,277 →
Application: 14/473,366 →
Publication: US US20140371222A1
Pyrrole Compounds That Modulate HSP90 Activity
Patent: 9,067,884 →
Application: 14/322,377 →
Publication: US US20150005299A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 9,120,745 →
Application: 14/285,834 →
Publication: US US20140296186A1
Method for Treating Proliferative Disorders Associated with Mutations in C-Met
Patent: 9,108,933 →
Application: 14/176,841 →
Publication: US US20140221375A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,937,094 →
Application: 13/941,081 →
Publication: US US20130303493A1
Pyrrole Compounds That Modulate HSP90 Activity
Patent: 8,785,658 →
Application: 13/902,290 →
Publication: US US20130261164A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,835,464 →
Application: 13/857,665 →
Publication: US US20130296378A1
Cancer Therapy Using a Combination of a HSP90 Inhibitory Compounds and a Egfr Inhibitor
Patent: 9,205,086 →
Application: 13/642,068 →
Publication: US US20130150385A1
Pyrazole Compounds That Modulate HSP90 Activity
Patent: 8,921,407 →
Application: 13/675,294 →
Publication: US US20130072536A1
Methods of Identifying HSP90 Inhibitors with Less Ocular Toxicity
Patent: 8,628,752 →
Application: 13/662,048 →
Publication: US US20130109045A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,901,308 →
Application: 13/550,324 →
Publication: US US20120330009A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,927,548 →
Application: 13/350,296 →
Publication: US US20120122869A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,486,932 →
Application: 13/333,191 →
Publication: US US20120101072A1
Hydrazonamide Compounds That Modulate Hsp90 Activity
Patent: 8,648,071 →
Application: 13/001,255 →
Publication: US US20120046288A1
Method for Treating Non-Hodgkin's Lymphoma
Patent: 9,101,614 →
Application: 13/227,130 →
Publication: US US20110319404A1
Method for treating a B-raf associated cancer with an Hsp90 inhibitor
Patent: 8,969,396 →
Application: 13/211,026 →
Publication: US US20110301212A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 9,126,953 →
Application: 13/057,962 →
Publication: US US20110224206A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,742,133 →
Application: 12/673,254 →
Publication: US US20110195094A1
Il-12 Modulatory Compounds
Patent: 8,263,764 →
Application: 12/978,356 →
Publication: US US20110294798A1
Method for Treating Proliferative Disorders Associated with Mutations in C-Met
Patent: 8,648,104 →
Application: 12/601,729 →
Publication: US US20100273846A1
Method for Inhibiting Topoisomerase Ii
Patent: 8,993,608 →
Application: 12/530,819 →
Publication: US US20100249185A1
Triazinone and Diazinone Derivatives Useful as HSP90 Inhibitors
Patent: 8,524,712 →
Application: 12/593,147 →
Publication: US US20100298331A1
Il-12 Modulatory Compounds
Patent: 8,236,795 →
Application: 12/731,056 →
Publication: US US20100256132A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,188,075 →
Application: 12/310,150 →
Publication: US US20100093717A1
Triazone Compounds That Modulate HSP90 Activity
Patent: 9,090,569 →
Application: 12/604,970 →
Publication: US US20110009397A1
Purine-Core Inhibitors of HSP90 and Their Use in Treating Cancer
Patent: 8,476,285 →
Application: 12/494,917 →
Publication: US US20100016586A1
Fused Hetrocyclic Compounds
Patent: 8,318,730 →
Application: 12/380,007 →
Publication: US US20090253694A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,183,384 →
Application: 11/807,331 →
Publication: US US20080004277A1
Method for Treating Non-Hodgkin's Lymphoma
Patent: 8,063,083 →
Application: 11/807,199 →
Publication: US US20080004276A1
Heteroaryl-Hydrazone Compounds
Patent: 7,935,698 →
Application: 10/985,716 →
Publication: US US20050282809A1
Fused Heterocyclic Compounds
Patent: 7,615,552 →
Application: 10/985,627 →
Publication: US US20050250770A1
Pyridine Compounds
Patent: 7,338,951 →
Application: 10/985,696 →
Publication: US US20050250774A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 8,053,456 →
Application: 11/807,327 →
Publication: US US20080176840A1
Method for Treating Proliferative Disorders with HSP90 Inhibitors
Patent: 8,034,834 →
Application: 11/807,354 →
Publication: US US20080004266A1
Therapeutic Compounds and Their Use in Cancer
Patent: 7,595,401 →
Application: 11/748,362 →
Publication: US US20070299258A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 7,662,813 →
Application: 11/506,185 →
Publication: US US20070155809A1
Imidazole Compounds That Modulate HSP90 Activity
Patent: 8,629,285 →
Application: 11/502,347 →
Publication: US US20070087998A1
Pyrazole Compounds That Modulate HSP90 Activity
Patent: 7,608,635 →
Application: 11/502,346 →
Publication: US US20070191445A1
Il-12 Modulatory Compounds
Patent: 7,863,270 →
Application: 11/433,603 →
Publication: US US20060281711A1
Pyrimidine Compounds and Uses Thereof
Patent: 7,851,466 →
Application: 11/282,926 →
Publication: US US20060135518A1
Triazole Compounds That Modulate HSP90 Activity
Patent: 7,825,148 →
Application: 11/282,119 →
Publication: US US20060167070A1
Process for Preparing Trisubstituted Pyrimidine Compounds
Patent: 7,923,557 →
Application: 11/271,568 →
Publication: US US20060122209A1
Heteroaryl Compounds
Patent: 7,919,487 →
Application: 11/271,704 →
Publication: US US20060122156A1
Il-12 Modulatory Compounds
Patent: 7,696,202 →
Application: 11/272,509 →
Publication: US US20060223996A1
2-Substituted Heteroaryl Compounds
Patent: 7,872,005 →
Application: 11/174,173 →
Publication: US US20060063739A1
Disalt Inhibitors of Il-12 Production
Patent: 7,745,436 →
Application: 11/105,818 →
Publication: US US20050282802A1
Related Assignments (23)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Dec 21, 2018
From: PROIA, DAVID
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 047839/0559 →
Assignment of Assignor's Interest Apr 18, 2019
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 048924/0851 →
Assignment of Assignor's Interest Jan 6, 2020
From: YING, WEIWEN; CHIMMANAMADA, DINESH U.; PROIA, DAVID
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 051422/0025 →
Assignment of Assignor's Interest Jan 6, 2020
From: JAIN, NEERA; YING, WEIWEN; CHIMMANAMADA, DINESH U.; ZHANG, JUNYI
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 051422/0240 →
Assignment of Assignor's Interest Jul 29, 2020
From: HESTER, D. KEITH, II; DUGUID, ROBERT J.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 053342/0966 →
Assignment of Assignor's Interest Jul 29, 2020
From: HESTER, D. KEITH, II; DUGUID, ROBERT J.; KELLY, MARTHA J.; CHASNOFF, ANNA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 053342/0941 →
Assignment of Assignor's Interest Aug 19, 2020
From: CHOI, DUK SOON; SHU, LIANHE; WANG, PING
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 053535/0741 →
Assignment of Assignor's Interest Feb 23, 2021
From: HESTER, D. KEITH, II; DUGUID, ROBERT J.; KELLY, MARTHA J.; CHASNOFF, ANNA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 055366/0031 →
Assignment of Assignor's Interest Feb 23, 2021
From: CHOI, DUK SOON; SHU, LIANHE; WANG, PING
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 055366/0065 →
Assignment of Assignor's Interest Feb 23, 2021
From: HESTER, D. KEITH, II; DUGUID, ROBERT J.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 055366/0061 →
Assignment of Assignor's Interest Jul 7, 2021
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 056778/0168 →
Assignment of Assignor's Interest Apr 21, 2023
From: CONFALONE, PASQUALE N.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 063395/0821 →
Assignment of Assignor's Interest Apr 21, 2023
From: CURIAL GLOBAL, INC.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 063395/0814 →
Assignment of Assignor's Interest Apr 21, 2023
From: VELLEKOOP, A. SAMUEL
To: CURIAL GLOBAL, INC.
Reel/Frame 063395/0785 →
Assignment of Assignor's Interest Aug 1, 2023
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 064451/0072 →
Assignment of Assignor's Interest Sep 26, 2023
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 065032/0678 →
Assignment of Assignor's Interest Dec 22, 2023
From: HESTER, D. KEITH, II; DUGUID, ROBERT J.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 065942/0863 →
Assignment of Assignor's Interest Dec 22, 2023
From: CHOI, DUK SOON; SHU, LIANHE; WANG, PING
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 065942/0852 →
Assignment of Assignor's Interest Dec 22, 2023
From: HESTER, D. KEITH, II; DUGUID, ROBERT J.; KELLY, MARTHA J.; CHASNOFF, ANNA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 065942/0829 →
Assignment of Assignor's Interest Apr 1, 2024
From: TAUB, REBECCA; CHIANG, EDWARD HUNG YANG
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 066962/0122 →
Assignment of Assignor's Interest Jun 12, 2025
From: TAUB, REBECCA; LABRIOLA, DOMINIC
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 071394/0422 →
Assignment of Assignor's Interest Nov 12, 2025
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 072882/0146 →
Assignment of Assignor's Interest Feb 26, 2026
From: TAUB, REBECCA
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 073902/0781 →